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AbsTrACT
Introduction We aimed to quantify health outcomes and 
programmatic implications of scaling up cervical cancer 
(CC) screening and treatment options for women living 
with HIV in care aged 18–65 in Kenya.
Methods Mathematical model comparing from 2020 
to 2040: (1) visual inspection with acetic acid (VIA) and 
cryotherapy (Cryo); (2) VIA and Cryo or loop excision 
electrical procedure (LEEP), as indicated; (3) human 
papillomavirus (HPV)- DNA testing and Cryo or LEEP; and 
(4) enhanced screening technologies (either same- day 
HPV- DNA testing or digitally enhanced VIA) and Cryo or 
LEEP. Outcomes measured were annual number of CC 
cases, deaths, screening and treatment interventions, and 
engaged in care (numbers screened, treated and cured) 
and five yearly age- standardised incidence.
results All options will reduce CC cases and deaths 
compared with no scale- up. Options 1–3 will perform 
similarly, averting approximately 28 000 (33%) CC cases 
and 7700 (27%) deaths. That is, VIA screening would 
yield minimal losses to follow- up (LTFU). Conversely, 
LTFU associated with HPV- DNA testing will yield a lower 
care engagement, despite better diagnostic performance. 
In contrast, option 4 would maximise health outcomes, 
averting 43 200 (50%) CC cases and 11 800 (40%) deaths, 
given greater care engagement. Yearly rescreening with 
either option will impose a substantial burden on the health 
system, which could be reduced by spacing out frequency 
to three yearly without undermining health gains.
Conclusions Beyond the specific choice of technologies 
to scale up, efficiently using available options will drive 
programmatic success. Addressing practical constraints 
around diagnostics’ performance and LTFU will be key to 
effectively avert CC cases and deaths.
InTroduCTIon
Cervical cancer (CC) remains a major cause 
of cancer- related morbidity and mortality 
among women globally, despite being largely 
preventable.1 Sub- Saharan Africa (SSA) has 
the highest CC incidence for a region in 
the world, likely due to both low coverage of 
preventative services and high prevalence of 
HIV.1 2 HIV is thought to increase the risk of 
acquiring cervical infection with human papil-
lomavirus (HPV) and developing cancerous 
lesions.3 4
Key questions
What is already known?
 ► Cervical cancer (CC) screening and treatment strat-
egies have been shown to be cost- effective and 
life- saving.
 ► Modelling studies to date have focused on the cost- 
effectiveness of CC screening and treatment options 
in hypothetical cohorts.
What are the new findings?
 ► This is the first study to evaluate the potential 
population- level impact of CC screening and treat-
ment interventions among women living with HIV 
(WHIV) in care by recreating the entire population of 
interest, including their demographic structure, their 
age and HIV- specific risk of human papillomavirus 
(HPV) disease progression and antiretroviral therapy 
initiation currently and over time.
 ► Also for the first time, this study assesses the scale- 
up of a country’s CC screening and treatment guide-
lines and identifies how intervention factors (eg, 
diagnostic performance, losses to follow- up) will 
affect programmatic success.
What do the new findings imply?
 ► Maximising health outcomes among WHIV in care in 
Kenya will rely more on the efficient use of available 
resources than on specific CC screening and treat-
ment technologies.
 ► A successful scale- up of HPV- DNA tests will require 
concerted efforts to minimise losses to follow- up 
(eg, single- visit, test- and- treat approach), while 
scaling up visual inspection methods will demand 
continuous provider training and technological im-
provements (eg, digitally enhanced imaging) to max-
imise its diagnostic performance.
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The WHO recently issued a call to eliminate CC.5 
They advise countries to aim for at least 70% coverage 
with CC screening and treatment services, in order to 
achieve population- level health gains, with women living 
with HIV (WHIV) signalled as a key target population.5 6 
Kenyan guidelines recommend screening WHIV for CC 
at HIV diagnosis and yearly thereafter.6 For WHIV, HPV- 
DNA tests are the screening method of choice, with prag-
matic approaches like visual inspection with acetic acid 
(VIA) as an alternative.7 Recommended treatments for 
precancerous lesions include cryotherapy (Cryo) and 
loop excision electrical procedure (LEEP).6 However, 
a recent national survey indicated that only 16.4% of 
eligible women, regardless of HIV status, had ever been 
screened for CC.8 Practical challenges to achieving 
screening targets include overall low acceptability of CC 
screening, high loss to follow- up (LTFU) rates, and infra-
structure and commodity constraints.9 10
We aim to quantify potential population- level health 
benefits of scaling up CC screening and treatment services 
among WHIV in care (ie, those on antiretroviral therapy 
(ART)) in the coming two decades and compare diag-
nostic and treatment options recommended by Kenyan 
guidelines to identify factors that could affect program-
matic success. This analysis aims to support ongoing 
policy and implementation discussions in Kenya and the 
wider SSA region.
MeTHods
Mathematical model
We adapted an existing individual- based model coded 
in C++ to represent the entire Kenyan population from 
1950 to 2035. The model design and mechanism has been 
described previously.11 12 The model runs in continuous 
time and simulates births, deaths, HIV infection, disease 
progression and treatment. Demographic events (eg, age 
composition in 1950, births and deaths) were assigned 
probabilistically, based on age- specific fertility and 
age and sex- specific mortality rates for Kenya from the 
United Nations World Population Prospects (UNWPP), 
accounting for changes over time (online supplementary 
figure S2).13 HIV- related events (eg, age and sex- specific 
HIV incidence, including paediatric infections), and 
access to ART, accounting for historic changes in CD4 
eligibility, were simulated based on data from the Joint 
United Nations Programme (UNAIDS) for Kenya.14 
CD4 count at seroconversion, disease progression and 
mortality were based on modelling estimates for SSA 
(online supplementary figure S3).15 Although individual- 
level ART adherence and failure were not explicitly 
modelled, the model recreated trends of ART coverage 
by age, sex and CD4 count at ART initiation over time.14
A validated natural history model of HPV infection and 
progression through mutually exclusive stages of related 
cervical disease was used.16 For the case of females aged 
15–65, events of cervical infection with HPV were assigned 
probabilistically, accounting for age and HIV- specific 
risk (figure 1). On infection with HPV, individuals prog-
ress through the mutually exclusive stages of cervical 
intraepithelial neoplasia (CIN) grade 1, CIN grade 2/3, 
carcinoma in situ and CC, or experience spontaneous 
recovery from HPV infection, CIN 1 or CIN 2/3.16 Tran-
sition through disease stages or spontaneous recovery 
was modelled probabilistically, also accounting for indi-
viduals’ age and HIV- related risk (online supplementary 
table S1).16 Individuals who recover from cervical disease 
were at risk of new infection events, assuming no gained 
immunity.16
The model makes four key assumptions about cervical 
disease progression among WHIV compared with HIV- 
negative women (figure 1A—red annotations, and online 
supplementary table S1):
 ► Higher risk of HPV infection.4
 ► Lower probability of recovering from HPV infection.4
 ► Higher risk of progression from HPV to CIN stages.3
 ► WHIV on ART for 2 years or more were assumed to 
have the same natural history as HIV- negative women.
HPV disease progression was modelled independent 
of CD4 count. Instead, duration on ART (≥2 years) was 
assumed to be a proxy of immunological reconstitution 
and, therefore, reduce the risk of cervical disease states, 
in line with recent robust evidence comparing time on 
ART for longer than 2 years to no or shorter term use.17
Model parameters (online supplementary table S1 and 
figure S1) were drawn from the literature, where available, 
or calibrated by exploring plausible ranges and fitting 
simultaneously to available Kenyan epidemiological data 
(online supplementary table S2).16 Epidemiological 
data were collated through an original systematic review 
and meta- analysis of age and HIV- specific prevalence of 
composite HPV (ie, any genotype) and of CIN 2/3, age- 
specific CC incidence and standardised incidence rate of 
CC among WHIV compared with HIV- negative women, 
as described in a recent publication from our group.16 
Briefly, we adhered to Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses and Meta- analyses 
of Observational Studies in Epidemiology recommenda-
tions for systematic reviews and meta- analyses,18 19 and 
searched Embase, Medline and the Cochrane Library, 
from inception to 30 May 2018, as well as grey literature. 
Data on the cervical disease outcomes of interest were 
pooled in a meta- analysis with random effects model.16 
Outcomes from the meta- analysis were used as calibra-
tion targets for the model parameters (online supple-
mentary material - figure S4).
scale-up of CC screening and treatment care options
From 2020 to 2040, the model compared the scale- up 
of the following four options to 70% coverage of WHIV 
in care (ie, WHIV on ART) aged between 18 and 65 
(figure 1B and table 1):
1. VIA- Cryo only: screening with VIA and, for those with 
a positive test, treatment with Cryo on the same visit in 
a pragmatic way (ie, regardless of Cryo eligible or not, 
assuming they were the only technologies available).
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Figure 1 (A) HPV natural history model and (B) outline of the options of care evaluated for scale- up. (A) Transition probabilities 
and rates vary by age and HIV status, as shown in blue and red annotations, respectively. Spontaneous recovery is possible 
from HPV and CIN stages. (B) Losses to follow- up (LTFU) are shown in red and occur when another visit to a health facility 
is necessary (ie, during HPV- DNA testing and from screening to LEEP). For definition and values of model parameters, see 
table 1. *Represents screening with either digitally enhanced VIA or same- day HPV- DNA. **Rescreening carried out yearly from 
2023 onwards (phase II), with pool of age- eligible WHIV in care being sampled each year at random for 70% coverage. ART, 
antiretroviral therapy; CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; Cryo, cryotherapy; 
HPV, human papillomavirus; LEEP, loop excision electrical procedure; LTFU, loss to follow- up; VIA, visual inspection with acetic 
acid; WHIV, women living with HIV.
2. VIA- Cryo plus LEEP: where, added to the above, LEEP 
was available for individuals with Cryo- ineligible le-
sions (assuming the need for referral to a specialised 
clinic).
3. HPV- DNA- Cryo plus LEEP: screening with HPV- DNA 
testing, which was assumed to require two visits (ie, 
one for testing and another to collect results) and 
treatment with either Cryo or LEEP. For HPV- DNA- 
positive women, Cryo was performed at collection of 
results or, if ineligible, LEEP on referral to a special-
ised clinic.
4. Enhanced technologies: where testing was assumed 
to be done with either same- day HPV- DNA testing 
or digitally enhanced VIA (ie, use of digital imaging 
devices to visualise VIA- stained cervix and increase its 
sensitivity to that of HPV- DNA testing). Treatment was 
performed with either Cryo during the same visit or 
LEEP on referral, given Cryo eligibility.
Options were modelled individually as a uniform 
(national- level) two- phase process scale- up strategy, 
to allow for comparisons. Phase I, from 2020 to 2022, 
consisted of a first delivery of the option to 70% of age- 
eligible WHIV in care. During phase II, from 2023 to 
2040, delivery was scaled up to target 70% of age- eligible 
WHIV in care annually, including WHIV who newly 
started ART. The sensitivity and specificity of screening 
tests and the efficacy of treatment options replicated 
reported parameters from recent Kenyan studies among 
WHIV in care (table 1). Also, rates of individuals refusing 
CC screening services and LTFU reflect those observed 
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Table 1 Parameters for CC screening and treatment options
Parameter Description Value (%) Reference
Diagnostic performance
VIA Values specific for detection of CIN 2+ lesions among 
WHIV in Kenya, irrespective of age or stage of cervical 
abnormality.
28
Sensitivity 62.70
Specificity 65.90
HPV- DNA
Sensitivity 83.60
Specificity 55.70
Treatment efficacy
Cryo (eligible lesions)* Values specific to WHIV in Kenya, irrespective of age or 
stage of cervical abnormality.
70 20
Cryo (ineligible lesions)* Efficacy was defined as the probability of remaining 
cervical disease free at 24 months after treatment.
35 Assumed
LEEP (Cryo ineligible)* For Cryo- ineligible lesions, the model assumed efficacy 
of Cryo to be half, in absence of empirical data.
80.20 21
Proportion of Cryo- ineligible* lesions
CIN 1 CIN 1 and CIS values were assumed. CIN 2/3 value from 
an implementation study from the Zambia, specifically 
using VIA without digital enhancement or other means for 
increased sensitivity.
0 43
CIN 2/3 16.70
CIS 100
Individuals refusing CC services Averaged value from two Kenyan surveys, one of which 
specifically included diagnosed WHIV in its sample.
13 22 23
LTFU
From testing with HPV- DNA to 
obtaining of results
Testing with HPV- DNA assumed to require two clinic 
visits (one for testing and one to obtaining results).
25 9 10
From obtaining results (either with VIA 
or HPV- DNA) to treatment with LEEP
Treatment with LEEP assumed to require referral to a 
specialised clinic.
49
*The model assumed that 16.7% of individuals with CIN 2/3 status and that all with CIS and CC status had signs of Cryo ineligibility. Per 
clinical practice guidelines, Cryo- eligible lesions are those that do not have signs of invasive cancer (eg, bleeding), that are visible in their 
entirety, that do not extend more than 2–3 mm into the endocervical canal (which should be normal in appearance) and that can be fully 
covered by the Cryo probe.
CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; Cryo, cryotherapy; HPV, human papillomavirus; LEEP, loop 
excision electrical procedure; LTFU, loss to follow- up; VIA, visual inspection with acetic acid; WHIV, women living with HIV.
in programmatic evaluations within HIV care facilities 
in Kenya.9 10 20–23 Individuals for whom treatment was 
effective and who recovered were assumed to remain 
cervical disease free for 24 months and, as above, go 
back to susceptible thereafter and be at risk of new HPV 
infections accounting for their age and ART status. The 
model assumed individuals’ LTFU during a specific year 
remained eligible for screening and treatment on subse-
quent years, as long as they remained within age eligi-
bility. For simplicity, no modes of differentiated care (eg, 
offering LEEP for those recurring with cervical disease 
regardless of their cervical status) were simulated. Also, 
the present modelling analyses do not consider any 
scale- up in screening and treatment activities among 
HIV- negative women.
For each option, we quantified the following outcomes:
 ► Number of incident CC cases and CC deaths.
 ► Age- standardised incidence of CC by 5- year periods 
(eg, 2020–2024, and so on), using the WHO popula-
tion and standardisation method.24
 ► Care engagement, including numbers screened, 
treated and cured.
 ► Number of screening tests performed, treatment 
administered and LTFU.
Outcomes were compared with a scenario with no 
scale- up in CC screening and treatment, henceforth 
referred to as status quo. Forward projections assumed 
a UNWPP medium variant in fertility and mortality, 
that HIV incidence remained stable at 2017 levels, that 
ART coverage reached UNAIDS 90:90:90 targets by 
2020 and remained stable thereafter. All results were 
based on an average of 100 model runs. Sensitivity anal-
yses were performed to account for uncertainty around 
target coverage, LTFU probabilities and frequency of 
rescreening, HIV incidence and ART coverage (online 
supplementary material).
To ensure transparency and reproducibility of our 
modelling analyses, we adhered to standardised guide-
lines for reporting of agent- based simulation studies, as 
further discussed in the online supplementary material 
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Figure 2 Predicted health outcomes of scaling up different options of cervical cancer (CC) screening and treatment. (A) 
Cumulative incident CC cases, (B) cumulative CC- related deaths, and (C) age- standardised incidence of CC per 100 000 
person- years. Cryo, cryotherapy; HPV, human papillomavirus; ICC, invasive cervical cancer; LEEP, loop excision electrical 
procedure; LTFU, loss to follow- up; VIA, visual inspection with acetic acid.
- table S7.25 All modelling estimates refer solely to the 
simulated population of WHIV in care.
Patient and public involvement
No patients or members of the public were involved in 
the design or carry- out of the present study.
resulTs
burden of HPV-related cervical disease under status quo
The model estimates that the population of WHIV in 
care in Kenya will increase from 0.91 million in 2020 to 
1.73 million in 2040, with their mean age rising from 37.5 
in 2020 to 44.1 in 2040. This will be driven by the effect 
of ART on extending their life expectancy. In the same 
period, the prevalence of HPV and CIN 2/3 is predicted 
to decrease from 55.8% and 7.6%, respectively, in 2020 
to 47.7% and 4.0%, respectively, in 2040. This decrease 
by 8.1% in HPV prevalence and by 3.6% in CIN 2/3 prev-
alence will mainly be driven by the protective effect of 
ART against HPV infection and progression to CIN 2/3. 
In the hypothetical absence of ART only a 3.6% and 0.8% 
reduction in HPV and CIN 2/3 prevalence, respectively, 
would be observed over the 20- year period, driven by a 
younger population of WHIV with a higher mortality, 
similar to the pre- ART era.
The above reduction in cervical HPV infection and 
precancerous lesions will result on an overall decrease 
in the age- standardised incidence of CC among 
WHIV from 241 per 100 000 women- years in 2020–
2024 to 218 per 100 000 women- years in 2035–2039 
(figure 2C). However, the predicted growth in popu-
lation numbers will drive a rise in the yearly number 
of incident CC cases and deaths among WHIV in care 
(). These will reach a cumulative total of 86 115 CC 
cases and 44 742 CC- related deaths between 2020 and 
2040 (figure 2A,B and supplementary material table 
S3).
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Figure 3 Predicted impact on the health system of scaling 
up cervical cancer (CC) screening and treatment options. (A) 
Percentage of CC cases averted (vs status quo) according 
to sensitivity and losses to follow- up of screening tests. (B) 
Care engagement. Treated refers to women who receive 
either Cryo or loop excision electrical procedure (LEEP) 
among those who are screen positive (ie, includes true and 
false positives); Cured refers to the number of women who 
were cured from a cervical intraepithelial neoplasia (CIN) 
lesion among those who were treated and had screened 
true positive. (C) Average number of screening tests, and 
Cryo and LEEP treatments administered per year in phase 
I (2020–2022) and phase II (2023–2040). Cryo, cryotherapy; 
HPV, human papillomavirus; ICC, invasive cervical cancer; 
VIA, visual inspection with acetic acid.
Impact of CC screening and treatment options
The model predicts that scaling up any of the CC 
screening and treatment options would achieve substan-
tial improvements in health outcomes (figure 2). VIA- 
Cryo only, VIA- Cryo plus LEEP and HPV- DNA- Cryo 
plus LEEP are expected to perform similarly, averting 
approximately 32.6% (28 000) of CC cases and 23.9% 
(10 702) of CC deaths by 2040, compared with status quo 
(figure 2A,B - and supplementary table S3). As a result, 
these three options would achieve a reduction in the age- 
standardised incidence of CC to 143 per 100 000 women- 
years by 2035–2039 (figure 2C - and supplementary table 
S3).
In contrast to the above, scaling up an option with 
enhanced technologies (ie, same- day HPV- DNA test 
or digitally enhanced VIA) could reduce CC cases and 
deaths by 50.2% (43 200) and 34.9% (15 612), respec-
tively (figure 2A,B - and supplementary table S3). The 
age- standardised incidence of CC would in turn reduce 
to 99 per 100 000 women- years by 2035–2039 (figure 2C 
- and supplementary table S3).
A number of factors explain the similar performance 
of the three options without enhanced technologies. On 
the one hand, LEEP availability will likely have its highest 
impact during phase I, when a higher proportion of indi-
viduals will present with Cryo- ineligible lesions. Yearly 
rescreening during later years (phase II) will allow for 
earlier detection of lesions at Cryo- eligible stages, thus 
reducing the need for LEEP (9.4% Cryo- ineligible lesions 
in phase I vs 1.0% in phase II). On the other hand, there 
will be a trade- off between the higher sensitivity of HPV- 
DNA testing and lower proportion of LTFU associated 
with same- day VIA- based options (figure 3A). Of all 
individual screening events over the 20- year period, an 
average of 35.8% (3.45 million) will be positive with VIA, 
compared with 50.2% (4.81 million) with an HPV- DNA 
test (figure 3B - and supplementary table S4). Despite the 
higher sensitivity of the latter, only 73.5% (3.54 million) 
of all of those with screen- positive results will receive 
treatment in the HPV- DNA- Cryo plus LEEP option (due 
to LTFU), compared with >97.9% (3.41 million) in both 
VIA- based options (figure 3A - and supplementary table 
S4). Moreover, the absolute cure rate (proportion cured 
among those treated with an actual precancerous lesion) 
will show a similar trend at 47.9% (0.22 million) compared 
with 59.1% (0.21 million), respectively (figure 3B - and 
supplementary table S4).
The trade- off between LTFU and test’s sensitivity will 
be seen across the whole spectrum of possible scenarios. 
For example, if sensitivity of VIA drops to 40% (ie, lowest 
reported values, given its operator- dependent nature) 
while maintaining LTFU at 0%, only 21.0% (18 084) of 
CC cases will be averted. Conversely, if the sensitivity of 
HPV- DNA testing decreases to 75% (ie, lower bound of 
reported CIs in the literature) at the same time its LTFU 
decreases from 25% to 10%, the proportion of CC cases 
averted will still be higher than baseline at 38.9% (33 
499).
The better health outcomes under the adoption of 
enhanced technologies will be the result of a substantial 
strengthening in care engagement. That is, treatment 
and true cure rates would be of 97.8% (5.13 million) and 
62.7% (0.32 million), respectively (figure 3B). Neither 
health gains nor care engagement would be substantially 
improved by increasing target programmatic coverage 
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beyond 70%. Moreover, health outcomes would not be 
undermined by spacing out the frequency of rescreening 
from yearly to three yearly (online supplementary mate-
rial - table S5 and S6).
The scale- up of any of the options will have an 
important impact on the health system in terms of diag-
nostic and treatment resources needed. Approximately 
9.6 million tests (either VIA or DNA) and 3.5 million 
treatments (either Cryo or LEEP) would be needed 
during the 20- year period with either of the three options 
that do not use enhanced technologies. To target 70% 
of WHIV at least once during phase I of either of these 
three options the health system will have to provide an 
average of 307 000 screening tests, 112 000 Cryo treat-
ments and, for the case of VIA- Cryo plus LEEP and HPV- 
DNA- Cryo plus LEEP, 11 700 LEEP treatments per year. 
These annual requirements would need to be scaled up 
in phase II in order to maintain rescreening and coverage 
targets. The proportional increase would be of approxi-
mately 155% (average of 483 000) and 154% (average of 
171 000 per year) for the case of screening tests and Cryo 
treatments (figure 3C). However, LEEP requirements 
would decrease by 86% (approximately 1600 per year—
figure 3C), as individuals with precancerous lesions are 
increasingly diagnosed at earlier, Cryo- eligible stages 
during phase II.
The average number of yearly tests administered 
with the use of enhanced technologies would need to 
increase by approximately 163% (from 320 000 per year 
in phase I to 530 000 in phase II), given the aforemen-
tioned optimised care engagement (figure 3B). Similarly, 
the number of Cryo treatments would increase by 165% 
(from 154 000 to 253 000 per year), and the number of 
LEEP treatments would decrease by 89% (from 16 000 
to 3000) (figure 3C). This intensive need for resources 
could be decreased by spacing out the frequency of 
rescreening in phase II from yearly to three yearly (online 
supplementary material).
dIsCussIon
Our results show that any of the CC screening and treat-
ment options recommended in Kenya for WHIV would 
translate to substantial population- level health gains. 
Despite the better diagnostic performance of HPV- DNA 
testing, its use will not result in superior health gains 
compared with the efficient use of VIA, unless LTFU is 
substantially minimised and, thus, engagement in care 
ensured. The adoption of enhanced CC screening tech-
nologies, such as same- day HPV- DNA testing or digitally 
enhanced VIA, could further improve health outcomes 
and care engagement. Our model also highlights that 
comprehensive treatment capabilities, including imme-
diate access to Cryo and a widespread availability of facil-
ities with LEEP capabilities, will be important to ensure 
maximal health benefits from the initial phases of service 
scale- up. As Kenya and other countries in the SSA region 
scale up CC screening and treatment services, there will 
be a need to be sensitive to health system constraints and 
not dismiss pragmatic options at the cost of preventable 
CC- related morbidity and mortality.
Our results are in line with previous evidence suggesting 
that integrated CC screening and treatment services into 
HIV care can be life- saving and that the added bene-
fits of HPV- DNA tests, compared with VIA, depend on 
ensuring LTFU is minimised.26 27 These and our results 
highlight key implications for health systems of SSA that, 
like Kenya, are looking to scale up CC screening coverage 
and respond to the WHO’s call to eliminate CC.
First, a significant and immediate decrease in the 
number of CC cases and deaths is possible with the 
scale- up of any option of services, especially while waiting 
for HPV vaccination to confer population- level protec-
tion. The availability of and capacity to provide CC 
screening and treatment services in SSA will differ by 
region and over time. Even in settings where resource 
constraints hinder the use HPV- DNA testing, the efficient 
use of VIA and Cryo only could yield significant reduc-
tions in the incidence and mortality of CC at the popu-
lation level. The latter, however, must be contextualised 
as a mean to scale up service delivery to be subsequently 
leveraged on to provide same- day HPV- DNA testing and/
or digitally enhanced VIA.
Second, while adopting HPV- DNA tests as the primary 
screening method is desirable to maximise individual and 
population- level health outcomes, phasing in this tech-
nology will require strengthening service delivery plat-
forms to ensure treatment with minimal LTFU. This is still 
not universally possible, either because of recommenda-
tions of two- step approaches (triage of HPV- DNA- positive 
women with VIA or cytology, which significantly decreases 
its diagnostic sensitivity) or resource constraints.6 28 
Nevertheless, transitioning to point- of- care, screen- and- 
treat HPV- DNA testing or digitally enhanced VIA has 
been shown to be possible in SSA after establishing basic 
infrastructure and human resources (eg, to provide VIA 
and Cryo).29–33 This can be particularly feasible in HIV 
care facilities, as WHIV represent a population regu-
larly accessing healthcare. Notably, digitally enhanced 
VIA warrants further evaluation before it can be recom-
mended as a screening technology with similar perfor-
mance to HPV- DNA testing. While mobile phone- based 
technologies are in development, which could facilitate 
its widespread adoption in resource- constrained settings, 
their evaluation outside trial conditions is still needed.33
Third, the availability of LEEP would be particularly 
important during the early stages of CC screening and 
treatment service scale- up. Its delivery requires special-
ised infrastructure to address potential complications, 
such as severe haemorrhages, which forestalls its avail-
ability in primary care facilities. Scale- up programmes in 
SSA have successfully expanded LEEP services by lever-
aging on provincial facilities.32 Moreover, the successful 
expansion of infrastructure to safely provide LEEP within 
low- resource HIV care facilities has been demonstrated.9 
Achieving this at a national scale in Kenya, while limiting 
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LTFU, could improve health gains during the early stages 
of service scale- up, when more women will present with 
advanced cervical lesions. Expanding LEEP availability 
will be an important factor to consider for screening 
programmes targeting WHIV, as they remain a popula-
tion at high risk of both residual and recurrent CIN 2+ 
cervical disease,34 and thus may need repeated screening 
and treatment with LEEP to minimise this risk.
Lastly, given expected population growth in SSA in the 
upcoming decades, resource needs of any CC screening 
programme will substantially increase over time. Health 
systems will need to plan for a large upfront investment in 
human resources and availability of commodities to reach 
a target coverage of 70% and rescreening frequency. Our 
model suggests this could be lessened by spacing out 
the frequency of rescreening recommendations to three 
yearly, in line with global recommendations,35 without 
repercussions on population- level health gains. Top- level 
discussions around the optimal frequency of rescreening 
towards achieving this goal must be informed by prospec-
tive programmatic evidence, with disaggregation by age 
and HIV status. Thus, any scale- up must be accompanied 
by a robust monitoring and evaluation framework that 
can effectively track programme performance.
To our knowledge, this is the first time a modelling 
study evaluates potential population- level impact of CC 
screening and treatment interventions by recreating 
the entire population of interest, including their demo-
graphic structure, their age and HIV- specific risk of HPV 
disease progression and ART initiation currently and over 
time. Moreover, this is the first study to assess the scale- up 
of a country’s CC screening and treatment guidelines 
and identify how intervention factors (eg, availability of 
specific technologies, diagnostic performance, LTFU) 
can affect programmatic success. Our analyses highlight 
that a phased scale- up of CC screening and treatment 
services for WHIV in Kenya will be crucial to achieve the 
2030 benchmarks set by the WHO towards CC elimina-
tion.5 We believe these results are applicable to other 
high- HIV burden countries and the directionality of the 
results to be applicable to HIV- negative populations. 
Previous models of CC among WHIV in SSA have focused 
on cohort approaches to produce key contributions to 
the cost- effectiveness literature of CC screening strate-
gies.26 27 36 However, population- level health outcomes 
have not been at the core of these studies, and simulated 
strategies have been outside of those recommended 
by national guidelines (eg, once in a lifetime) and/or 
targeted idealised cohorts (where infection with HIV and 
treatment with ART happens statically at an early age).
Several limitations to our modelling analyses must 
be acknowledged. First, the model made a simplified 
assumption that WHIV on ART for ≥2 years had the 
same natural history of HPV- related disease as HIV- 
negative women, and ART adherence and failure were 
not explicitly modelled. Our assumptions may result in 
an overestimation of the protective effect of ART against 
HPV- related cervical disease and therefore underestimate 
the impact of the simulated CC screening and treat-
ment strategies. However, the comparative impact of 
the different options modelled would not differ. These 
assumptions were based on most recent evidence in the 
field,3 4 17 and the model performed well when compared 
with HIV- specific epidemiological data from Kenya on 
various stages of cervical disease (online supplementary 
material). Second, the model assumed that HPV epide-
miological data mainly collected from urban populations 
in Kenya were applicable to the whole country. While this 
may result in a different crude national- level burden of 
HPV- related cervical disease among WHIV (depending 
on urban/rural risk distribution), the proportion and 
directionality of our results are unlikely to change. 
Prospectively collected data, disaggregated by region and 
HIV status, will be key for better parameterising future 
modelling analyses. Third, no data are available from 
Kenya regarding population- level CC mortality rates and 
we thus fitted the model against available estimates for 
the country from The Global Burden of Disease and 
Globocan.37 38 This approach inherently introduces 
external assumptions embedded in the modelling esti-
mates from these two sources. Any estimation of CC 
deaths will, as a result, be an overestimation or underesti-
mation of the true population- level mortality. However, in 
our mortality fit we ensured no assumptions on changes 
to future trends of CC mortality were made, aiming to 
represent what would be seen under status quo. Data from 
nationally representative cancer registries are necessary 
to better inform future analyses. Finally, the model did 
not account for any vaccination- related immunity against 
HPV in the population. While a national campaign 
to vaccinate school- aged girls has been announced in 
Kenya, there are no estimates of coverage rates in the 
country.39 If a national- level HPV vaccination campaign, 
with a catch- up component for girls older than 15 
years, was to be rolled out in the near future, the role 
of CC screening and treatment in preventing morbidity 
and mortality would be lessened over time. However, 
if such vaccination catch- up component is not imple-
mented, population- level protection would be delayed 
for decades.40 Moreover, until nationwide vaccination 
programmes are fully implemented, screening and treat-
ment of precancerous cervical lesion remains the best 
option to avert CC. Importantly, while immunogenicity 
studies suggest WHIV achieve protection levels against 
HPV strains similar to those of HIV- negative women,41 
long- term prospective studies to assess clinical outcomes 
among vaccinated adolescent WHIV are missing.
Further research is needed to clarify the economic 
implications of scaling up national preventative 
programmes towards achieving the goal of CC elimi-
nation among both WHIV and HIV- negative women. 
No study has looked into the cost benefit and cost 
equity of such CC preventative interventions, nor the 
potential impact of increasing heard immunity against 
HPV (ie, as a result of vaccination) on the efficiency of 
screening programmes. Accurate data collection on cost 
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elements and the above analyses would be key to inform 
relevant policy and funding discussions in the coming 
years, as countries gear up to scale up CC preventative 
efforts. There is also an evidence gap of large- scale trials 
comparing cervical disease outcomes between Cryo abla-
tion for women with an HPV- DNA- positive test without 
versus already with cervical lesions. Current evidence 
shows the former approach can lead to higher cervical 
disease- free (CIN 2+) rates.35 42
Kenyan recommendations for HPV- DNA testing as 
the primary screening method for WHIV and the WHO 
call to eliminate CC are ambitious. As health systems in 
Kenya and the wider SSA region work to scale up CC 
preventative services, different options of screening 
and treatment technologies are at their disposal. The 
emphasis, however, needs to remain on providing down-
stream treatment for those positively diagnosed in order 
to avert CC cases and deaths. Our analyses show that 
either of these options will have a positive impact on 
the health of WHIV in care, but potential challenges to 
their implementation must be critically assessed by poli-
cymakers and programme managers. Beyond opting for 
better performing technologies, it will be the quality of 
implementation of CC screening and treatment scale- up 
that will drive programmatic success. Health systems 
choosing to scale up HPV- DNA testing will need to do 
so hand in hand with concerted efforts to minimise 
LTFU. Conversely, those choosing to scale up VIA will 
need to emphasise continuous provider training and 
technological improvements to maximise its diagnostic 
performance. Additionally, comprehensive treatment 
capabilities, including immediate access to Cryo and a 
widespread availability of referral facilities to perform 
LEEP, will be key to maximise health outcomes from the 
initial phases of service scale- up. Foremost, health systems 
in SSA must aim for an early and sustainable engagement 
of patients in CC screening and treatment services by 
efficiently employing currently available technologies, 
thereby effectively reducing CC morbidity and mortality.
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